Trials / Completed
CompletedNCT05376670
Patient Satisfaction and Long-term Safety of Intravesical Aminoglycoside Instillations in UTI Prevention
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Leiden University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Antimicrobial prophylactic treatment of recurrent UTI is limited by emerging resistance, antibiotic allergies and intolerances. Intravesical aminoglycoside instillations (IAI) have been shown to reduce recurrence rate, without a short-term decline in kidney function or hearing. Thus far, treatment satisfaction has not yet been assessed, while this may play an important role in treatment adherence and persistence. Moreover, there is no data on the long-term safety of IAI, e.g. regarding the development of (pre)malignant bladder lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravesical aminoglycoside instillations | Overnight instillation of an aminoglycoside (CIC), varying treatment regimens |
Timeline
- Start date
- 2022-04-20
- Primary completion
- 2023-03-07
- Completion
- 2023-03-07
- First posted
- 2022-05-17
- Last updated
- 2023-03-08
Locations
1 site across 1 country: Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05376670. Inclusion in this directory is not an endorsement.